Woojin B&G Secures Approval for G2b Variant PED Vaccine, Targets 30% Market Share

Woojin B&G has obtained regulatory approval for a live vaccine targeting the G2b strain variant of porcine epidemic diarrhea (PED), which is currently prevalent in domestic pig farms, and is set to launch an aggressive market push. The company is also accelerating the development of a follow-up pipeline for a swine influenza vaccine, intensifying efforts to expand its animal vaccine business.

On August 27, Woojin B&G announced that it had received official product approval for its live PED vaccine, “Immunis PED-M Live.”

PED is a major viral disease that causes severe watery diarrhea and dehydration in young piglets, often leading to high mortality rates. Recently, the G2b strain variant, which is antigenically different from existing vaccine strains, has been spreading rapidly across Korean pig farms, creating strong demand for a vaccine that can address this new variant.

The newly approved Immunis PED-M Live was developed based on the G2b-type PED virus currently circulating in Korea. Woojin B&G expects this vaccine to provide protective effects against the variant strains.

Notably, the vaccine has been approved for use via two administration routes: intramuscular injection and oral dosing. This allows farms to choose the most suitable mode of administration according to their breeding environment and vaccination programs, thereby enhancing its practicality in the field.

Building on this product approval, Woojin B&G aims to increase its share of the domestic PED vaccine market to over 30 percent. The company expects that commercializing the research results on prevailing variant strains will differentiate Immunis PED-M Live from conventional vaccines and strengthen its competitive advantage.

A company representative stated, “It is significant that we have translated research findings on domestic variant strains into a commercially viable vaccine. By emphasizing the convenience of the two administration routes, we aim to grow our market share of the domestic PED vaccine segment to over 30 percent and enhance our competitiveness in the global market as well.”

Development of follow-up pipelines is also underway. Woojin B&G is fast-tracking the creation of a next-generation animal vaccine against swine influenza.

The product under development is a trivalent inactivated vaccine targeting three viral subtypes: H1N1, H1N2, and H3N2. Swine influenza is a respiratory disease occurring among pigs that can also transmit to humans as a zoonotic infection. With recent reports of human cases overseas, the importance of preventative vaccination is growing.

Drawing on accumulated research data, Woojin B&G has finalized the specific development criteria for the swine influenza vaccine and is proceeding with subsequent steps. The company plans to commence field trials within this year.

With the recent approval of the PED vaccine and the ongoing development of the swine influenza vaccine, Woojin B&G’s animal vaccine business portfolio is expected to expand further. The company plans to secure product competitiveness in the domestic pig farming market while also preparing to enter the global market in the future.

This content was produced with the assistance of AI translation services.